Solid Biosciences Debt
| SLDB Stock | USD 5.69 0.09 1.56% |
Solid Biosciences LLC holds a debt-to-equity ratio of 0.154. At present, Solid Biosciences' Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting. The current year's Net Debt To EBITDA is expected to grow to 0.54, whereas Net Debt is forecasted to decline to (50.1 M). With a high degree of financial leverage come high-interest payments, which usually reduce Solid Biosciences' Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
Solid Biosciences' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Solid Biosciences' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Solid Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Solid Biosciences' stakeholders.
For most companies, including Solid Biosciences, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Solid Biosciences LLC, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Solid Biosciences' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 1.3611 | Book Value 4.29 | Return On Assets (0.35) | Return On Equity (0.66) |
Solid |
Solid Biosciences Bond Ratings
Solid Biosciences LLC financial ratings play a critical role in determining how much Solid Biosciences have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Solid Biosciences' borrowing costs.| Piotroski F Score | 4 | Poor | View |
| Beneish M Score | (3.14) | Unlikely Manipulator | View |
Solid Biosciences LLC Debt to Cash Allocation
As Solid Biosciences LLC follows its natural business cycle, the capital allocation decisions will not magically go away. Solid Biosciences' decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors.
Solid Biosciences LLC currently holds 26.27 M in liabilities with Debt to Equity (D/E) ratio of 0.15, which may suggest the company is not taking enough advantage from borrowing. Solid Biosciences LLC has a current ratio of 7.69, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Solid Biosciences' use of debt, we should always consider it together with its cash and equity.Solid Biosciences Total Assets Over Time
Solid Biosciences Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Solid Biosciences uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Solid Biosciences Debt Ratio | 17.0 |
Solid Biosciences Corporate Bonds Issued
Most Solid bonds can be classified according to their maturity, which is the date when Solid Biosciences LLC has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Solid Net Debt
Net Debt |
|
Understaning Solid Biosciences Use of Financial Leverage
Solid Biosciences' financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures Solid Biosciences' total debt position, including all outstanding debt obligations, and compares it with Solid Biosciences' equity. Financial leverage can amplify the potential profits to Solid Biosciences' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if Solid Biosciences is unable to cover its debt costs.
| Last Reported | Projected for Next Year | ||
| Net Debt | -47.8 M | -50.1 M | |
| Short and Long Term Debt Total | 26.3 M | 27.6 M | |
| Long Term Debt Total | 659.7 K | 636.8 K | |
| Short Term Debt | 4.6 M | 3.5 M | |
| Net Debt To EBITDA | 0.51 | 0.54 | |
| Debt To Equity | 0.21 | 0.22 | |
| Interest Debt Per Share | 1.32 | 1.27 | |
| Debt To Assets | 0.16 | 0.17 | |
| Long Term Debt To Capitalization | 0.16 | 0.17 | |
| Total Debt To Capitalization | 0.17 | 0.18 | |
| Debt Equity Ratio | 0.21 | 0.22 | |
| Debt Ratio | 0.16 | 0.17 | |
| Cash Flow To Debt Ratio | (3.59) | (3.77) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Solid Biosciences LLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Solid Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Solid Biosciences Llc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Solid Biosciences Llc Stock:Check out the analysis of Solid Biosciences Fundamentals Over Time. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Solid Biosciences. If investors know Solid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Solid Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.04) | Quarterly Revenue Growth (1.00) | Return On Assets (0.35) | Return On Equity (0.66) |
The market value of Solid Biosciences LLC is measured differently than its book value, which is the value of Solid that is recorded on the company's balance sheet. Investors also form their own opinion of Solid Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Solid Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Solid Biosciences' market value can be influenced by many factors that don't directly affect Solid Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Solid Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Solid Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Solid Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.